All In Biotech

Drug Trial Radar · NCT04093596

Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

73

Actual

Start

Sep 23, 2019

Primary completion

Jan 27, 2025

Study completion Jan 27, 2025

Sponsor

Lead sponsor
Allogene TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone.

Conditions

  • Relapsed/Refractory Multiple Myeloma

Interventions

  • ALLO-715Genetic

    ALLO-715 is an allogeneic CAR T cell therapy targeting BCMA

  • ALLO-647Biological

    ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen

  • FludarabineDrug

    Chemotherapy for lymphodepletion

  • CyclophosphamideDrug

    Chemotherapy for lymphodepletion

  • NirogacestatDrug

    a small molecule, selective, reversible, noncompetitive inhibitor of γsecretase (GSI) that increases BCMA target density on the surface of multiple myeloma cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-715Time frame: 28 Days
  2. To assess the overall safety profile and tolerability of ALLO-647 in combination with Fludarabine and/or cyclophosphamide or ALLO-647 alone, prior to ALLO-715 to confirm the dose of ALLO-647.Time frame: 33 days
  3. To assess the overall safety profile and tolerability of nirogacestat given concomitantly with ALLO-715 following lymphodepletion with Flu/ Cy/ ALLO-647.Time frame: 28 days

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • City of Hope

    Duarte, California

  • Stanford Cancer Institute

    Palo Alto, California

  • Sarah Cannon/Colorado Blood Cancer Institute

    Denver, Colorado

  • Mayo Clinic

    Rochester, Minnesota

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Cleveland Clinic Taussig Cancer Center

    Cleveland, Ohio

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • St. David's South Austin Medical Center

    Austin, Texas

  • Texas Transplant Institute

    San Antonio, Texas

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.